KYNTRA BIO INC

KYNBNASDAQ

🏆 #3513 by market capEarnings Aug 13US Equity

$7.07▲ $0.01 (+0.14%)

Market closed · at close

1h—

24h▲ 0.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$29M

Small Cap

📈Revenue Growth (YoY)

-78.3%

Declining

📊Gross Margin

45.1%

Healthy

💵FCF Margin

-287.7%

Thin

⚖️P/S Ratio

3.8x

Fair

Otter Score

Weak

No chart data available for KYNB.

Trading Snapshot

Day Range: $7.02 – $7.11
52-Week Range: $6.32 – $12.60
Volume: $3.82B
Avg Volume: $3.02B
Shares Outstanding: 4.0M
Next Earnings: Sep 19, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $4M
P/E Ratio: 0.1
P/S Ratio: 3.8x
EPS (TTM): $40.43
Dividend Yield: 0.00%

Why Investors Own KYNB

✓High-growth profile — revenue up +36.4% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▲ +38.0% YoY

Gross Margin (TTM)

25.7%▲ +3.2% YoY

Operating Income (TTM)

$1M▲ +38.0% YoY

Free Cash Flow (TTM)

$1M▲ +38.0% YoY

About KYNTRA BIO INC

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

🦦